Puma Biotechnology | PBYI - Ebit


Puma Biotechnology reported $-2.2M in EBIT for its fiscal quarter ending in June of 2024.





Ebit Change Date
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amgen USD 4.68B 65M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Daiichi Sankyo JPY 108.7B 23.6B Sep/2026
Exelixis USD 268.42M 20.01M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Glaxosmithkline GBP 2.15B 157M Sep/2026
Incyte USD -707.47M 1.41B Sep/2026
MacroGenics USD -65.25M 33.36M Jun/2026
Moderna USD 130M 945M Sep/2026
Novartis USD 5.14B 411M Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
PTC Therapeutics USD 146.03M 100.14M Jun/2026
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
Takeda JPY 205.32B 3.9B Sep/2026
TG Therapeutics USD 21.67M 13.12M Jun/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Vanda Pharmaceuticals USD -10.28M 721K Dec/2024
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026